MAP2K7 and melanoma: In addition, no objective responses to single-agent treatment were reported in non-melanoma patients in phase 1 trials of the MEK inhibitors selumetinib (NCT00085787) (Adjei et al, 2008), cobimetinib (NCT00467779) (Rosen et al, 2011), or pimasertib (NCT00982865) (Delord et al, 2010).